Denosumab
Also known as: Prolia · Xgeva · Jubbonti · Wyost · Xbryk · Obodence · Osenvelt · Stoboclo · Jubereq · Osvyrti
General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).
In short
In the European Union, denosumab is indicated for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In the European Union, it is also indicated for the prevention of skeletal-related events in adults with advanced malignancies involving bone, and for the treatment of giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity in adults and skeletally mature adolescents. In the United States, denosumab is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, for the treatment of unresectable or high-morbidity giant cell tumor of bone in adults and skeletally mature adolescents, and for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.
From: Source: European Medicines Agency (EMA), Prolia — EPAR, 19/08/2026. © European Medicines Agency. · Source: European Medicines Agency (EMA), Xgeva — EPAR, 30/06/2026. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration.
AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.
Codes
- RxNorm
- 993449 denosumab
- EMA
- EMEA/H/C/001120, EMEA/H/C/002173, EMEA/H/C/005964, EMEA/H/C/006378, EMEA/H/C/006468, EMEA/H/C/006424, EMEA/H/C/006157, EMEA/H/C/006156, EMEA/H/C/006398, EMEA/H/C/006399, EMEA/H/C/006437, EMEA/H/C/006436, EMEA/H/C/006534, EMEA/H/C/006199, EMEA/H/C/006376, EMEA/H/C/006377, EMEA/H/C/006152, EMEA/H/C/006526, EMEA/H/C/006269, EMEA/H/C/006507, EMEA/H/C/006268, EMEA/H/C/006435, EMEA/H/C/006434, EMEA/H/C/006239, EMEA/H/C/006722, EMEA/H/C/006490, EMEA/H/C/006734, EMEA/H/C/006238, EMEA/H/C/006552, EMEA/H/C/006492, EMEA/H/C/006626
Official indications
Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.
FDA (USA) Bilprevda
1 INDICATIONS AND USAGE Bilprevda is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 ) 1.1 Multiple Myeloma and Bone Metastasis from Solid Tumors Bilprevda is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. 1.2 Giant Cell Tumor of Bone Bilprevda is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [see Clinical Trials ( 14.2 )] . 1.3 Hypercalcemia of Malignancy Bilprevda is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.
Data provided by the U.S. Food and Drug Administration.
Document date: 20260818 · Official document →
EMA (EU) Prolia
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Prolia significantly reduces the risk of vertebral, non vertebral and hip fractures. Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Prolia significantly reduces the risk of vertebral fractures.
Source: European Medicines Agency (EMA), Prolia — EPAR, 19/08/2026. © European Medicines Agency.
Document date: 19/08/2026 · Official document →
EMA (EU) Xgeva
Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1). Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
Source: European Medicines Agency (EMA), Xgeva — EPAR, 30/06/2026. © European Medicines Agency.
Document date: 30/06/2026 · Official document →
Other treatments A–Z
What people report
Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.
External resources
Questions
What is Denosumab approved for in the European Union?
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Prolia significantly reduces the risk of vertebral, non vertebral and hip fractures. Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Prolia significantly reduces the risk of vertebral fractures. (Source: European Medicines Agency (EMA), Prolia — EPAR, 19/08/2026. © European Medicines Agency.)
Sources and attribution
- Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
- Data provided by the U.S. Food and Drug Administration.
- Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
- This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
- Source: European Medicines Agency (EMA), Prolia — EPAR, 19/08/2026. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Xgeva — EPAR, 30/06/2026. © European Medicines Agency.
Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →
About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.
Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.
What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.
Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.
In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.